Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease | Zendy

Trevor L. Schell | Zendy; Keith L. Knutson | Zendy; Sumona Saha | Zendy; Arnold Wald | Zendy; Hiep Phan | Zendy; Mazen Almasry | Zendy; Kelly Chun | Zendy; Ian Grimes | Zendy; Megan Lutz | Zendy; Mary S. Hayney | Zendy; Francis A. Farraye | Zendy; Freddy Caldera | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease

Author(s) -

Trevor L. Schell,

Keith L. Knutson,

Sumona Saha,

Arnold Wald,

Hiep Phan,

Mazen Almasry,

Kelly Chun,

Ian Grimes,

Megan Lutz,

Mary S. Hayney,

Francis A. Farraye,

Freddy Caldera

Publication year - 2022

Publication title -

inflammatory bowel diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.932

H-Index - 146

eISSN - 1536-4844

pISSN - 1078-0998

DOI - 10.1093/ibd/izac082

Subject(s) - immunogenicity , inflammatory bowel disease , covid-19 , medicine , immunology , messenger rna , disease , virology , immune system , biology , outbreak , infectious disease (medical specialty) , gene , biochemistry

Lay Summary Herein, we evaluated the humoral immunogenicity of a third coronavirus disease 2019 messenger RNA vaccine dose in patients with inflammatory bowel diseases. All patients displayed a humoral immune response, and median antibody concentrations were higher after the third dose than after completion of the 2-dose series.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research